These findings unveil that γδT cells can serve as crucial effectors in ICIs therapy for combating HLA-I/B2M-deficient cancers, which represent a novel mechanism and therapeutic approach for monitoring tumor immune resistance. The gene discussed is B2M; the disease is cancer.